Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) keeps evolving and mutating into newer variants over time, which gain higher transmissibility, disease severity, and spread in communities at a faster rate, resulting in multiple waves of surge in Coronavirus Disease 2019 (COVID-19) cases. A highly mutated and transmissible SARS-CoV-2 Omicron variant has recently emerged, driving the extremely high peak of infections in almost all continents at an unprecedented speed and scale. The Omicron variant evades the protection rendered by vaccine-induced antibodies and natural infection, as well as overpowers the antibody-based immunotherapies, raising the concerns of current effectiveness of available vaccines and monoclonal antibody-based therapies. This review outlines the most recent advancements in studying the virology and biology of the Omicron variant, highlighting its increased resistance to current antibody-based therapeutics and its immune escape against vaccines. However, the Omicron variant is highly sensitive to viral fusion inhibitors targeting the HR1 motif in the spike protein, enzyme inhibitors, involving the endosomal fusion pathway, and ACE2-based entry inhibitors. Omicron variant-associated infectivity and entry mechanisms of Omicron variant are essentially distinct from previous characterized variants. Innate sensing and immune evasion of SARS-CoV-2 and T cell immunity to the virus provide new perspectives of vaccine and drug development. These findings are important for understanding SARS-CoV-2 viral biology and advances in developing vaccines, antibody-based therapies, and more effective strategies to mitigate the transmission of the Omicron variant or the next SARS-CoV-2 variant of concern.

Challenges and developments in universal vaccine design against SARS-CoV-2 variants

The Challenge of Emerging SARS-CoV-2 Mutants to Vaccine Development

SARS-CoV-2: Mapping its features that made it as a unique virus

Revisiting the dimensions of universal vaccine with special focus on COVID-19: Efficacy versus methods of designing

Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape

Severe acute respiratory syndrome coronavirus 2 variants-Possibility of universal vaccine design: A review

Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants

Advances in the Design and Development of SARS-CoV-2 Vaccines

Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants

Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines

The way of SARS-CoV-2 vaccine development: success and challenges

Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances to Counter the SARS-CoV-2 Omicron Variant

Challenges and Recent Advancements in COVID-19 Vaccines

Progress and perspectives of universal influenza vaccine

COVID-19 Variants and Vaccine Development

Universal protection against SARS-CoV-2 viruses by multivalent mRNA vaccine in mice

Evaluation of Immunoprotection Against Coronavirus Disease 2019: Novel Variants, Vaccine Inoculation, and Complications

Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines

Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development

SARS-CoV-2 Variants, Immune Escape, and Countermeasures

An Immunoinformatic Approach for Identifying and Designing Conserved Multi-Epitope Vaccines for Coronaviruses